Progressive Supranuclear Palsy - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H2 2016, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Progressive Supranuclear Palsy Overview 7
Therapeutics Development 8
Pipeline Products for Progressive Supranuclear Palsy - Overview 8
Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis 9
Progressive Supranuclear Palsy - Therapeutics under Development by Companies 10
Progressive Supranuclear Palsy - Therapeutics under Investigation by Universities/Institutes 11
Progressive Supranuclear Palsy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Progressive Supranuclear Palsy - Products under Development by Companies 15
Progressive Supranuclear Palsy - Products under Investigation by Universities/Institutes 16
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 17
AB Science SA 17
AbbVie Inc 18
AlzProtect SAS 19
Asceneuron SA 20
Bristol-Myers Squibb Company 21
Cortice Biosciences Inc 22
Intellect Neurosciences Inc 23
Prana Biotechnology Ltd 24
Sellas Inc 25
TauRx Therapeutics Ltd 26
Progressive Supranuclear Palsy - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ABBV-8E12 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ASN-561 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AZP-2006 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
BMS-986168 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
DC-TAB - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
DPC-016 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
masitinib - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
MK-8719 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
PBT-434 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
TauC-3 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
tolfenamic acid - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TPI-287 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
TRx-0237 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
zolpidem tartrate - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Progressive Supranuclear Palsy - Dormant Projects 71
Progressive Supranuclear Palsy - Product Development Milestones 72
Featured News & Press Releases 72
Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy 72
Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy 72
Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases 73
Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 73
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, H2 2016 8
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Progressive Supranuclear Palsy - Pipeline by AB Science SA, H2 2016 17
Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H2 2016 18
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H2 2016 19
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H2 2016 20
Progressive Supranuclear Palsy - Pipeline by Bristol-Myers Squibb Company, H2 2016 21
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H2 2016 22
Progressive Supranuclear Palsy - Pipeline by Intellect Neurosciences Inc, H2 2016 23
Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Ltd, H2 2016 24
Progressive Supranuclear Palsy - Pipeline by Sellas Inc, H2 2016 25
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Progressive Supranuclear Palsy - Dormant Projects, H2 2016 71